Enrique Maldonado Corchado, MD
Endocrinology, Diabetes & Metabolism · Guaynabo, PRNPI 1972873792
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,809 of the $8,235 with a category attached, or 82.7%. It is spread thinly across 29 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,775 and has fallen 79.1% since, to $579 in 2025.
Across 367 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$2K
- Novo Nordisk$1K
- Amgen$808
- Bayer Puerto Rico Inc.$679
- Abbott$579
- AstraZeneca$544
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$1,40017%
- Food & beverage$6,80983%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 19 | $1,722 |
| Novo Nordisk | 70 | $1,265 |
| Amgen(2 entities) | 35 | $808 |
| Bayer Puerto Rico Inc. | 30 | $679 |
| Abbott | 18 | $579 |
| AstraZeneca(2 entities) | 34 | $544 |
| Merck | 31 | $442 |
| Boehringer Ingelheim | 15 | $281 |
| Eli Lilly Export S.A. Puerto Rico Branch | 9 | $205 |
| AbbVie | 12 | $201 |
| Lilly USA, LLC | 12 | $185 |
| Johnson & Johnson | 16 | $178 |
| Dexcom, Inc. | 9 | $177 |
| Mannkind Corporation | 11 | $161 |
| Bayer | 8 | $154 |
| Sanofi-aventis U.S. LLC | 7 | $145 |
| Valeritas, Inc. | 9 | $134 |
| Shire North American Group Inc | 5 | $77 |
| Amarin Pharma, Inc. | 4 | $71 |
| PBG Puerto Rico LLC | 2 | $45 |
| Medtronic | 2 | $32 |
| Novartis | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 2 | $24 |
| BD | 1 | $22 |
| Companion Medical, Inc. | 1 | $19 |
| Lifescan, Inc. | 1 | $19 |
| Insulet Corporation | 1 | $16 |
| IBSA Pharma Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$1,400
- FREESTYLE LIBRE 3$267
- Repatha$125
- RYBELSUS$113
How this compares
$8,235 in reported general payments places this provider in the 70th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 13 | $516,798 |
| OzempicSemaglutide | 482 | $487,906 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 392 | $300,649 |
| MounjaroTirzepatide | 229 | $255,951 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 264 | $198,378 |
| TrulicityDulaglutide | 188 | $193,351 |
| JardianceEmpagliflozin | 166 | $111,114 |
| GlyxambiEmpagliflozin/Linagliptin | 141 | $101,598 |
| Xigduo XrDapaglifloz Propaned/Metformin | 161 | $96,939 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 135 | $95,776 |
| FarxigaDapagliflozin Propanediol | 124 | $83,519 |
| SynthroidLevothyroxine Sodium | 993 | $73,149 |
| RybelsusSemaglutide | 60 | $71,977 |
| Humalog Kwikpen U-200Insulin Lispro | 42 | $65,910 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 94 | $60,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Trijardy Xr, Jardiance, Glyxambi, Jentadueto Xr | $281 | $759,8381,044 claims |
| Novo NordiskOzempic, Rybelsus | $1,265 | $559,883542 claims |
| Corcept TherapeuticsKorlym | $1,722 | $516,79813 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Humulin 70-30 | $185 | $497,529671 claims |
| MerckJanumet Xr, Januvia, Janumet | $442 | $99,553154 claims |
| AstraZenecaFarxiga | $544 | $83,519124 claims |
| AbbVieSynthroid | $201 | $73,149993 claims |
| Sanofi-aventis U.S. LLCLantus, Soliqua 100-33 | $145 | $49,097404 claims |
| BayerKerendia | $154 | $30,48938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Guaynabo
- Ernesto Sola SanchezGuaynabo$12K
- Marina Torres TorresGuaynabo$7K
- Jose Garcia MateoPonce$945K
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
- Meliza Martinez RodriguezSan Juan$80K
- Milliette Alvarado SantiagoRio Piedras$75K
- Altagracia Alcantara GonzalezBayamon$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.